No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 17
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T12:05:19.459Z. Latest historical point 2026-03-27. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Adagio Medical Holdings, Inc. (ADGM) stock was $0.14 as of Oct 5, 2026, 4:00 PM EDT, down 7.84% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -92.9%
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies.
Medical - Devices · Laguna Hills, CA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.25
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.30
vs Estimate
$-0.27
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ADGM | $3.13M | $0.14 | -7.84% | -92.86% | N/A | N/A | N/A |
| 2BRTX | $3.09M | $2.24 | +4.67% | -92.40% | -61.44% | -68.97% | vs ADGM |
| 3CVKD | $3.37M | $0.95 | +0.60% | -93.24% | N/A | N/A | vs ADGM |
| 4AEMD | $3.44M | $6.53 | +1.16% | -83.19% | -78.27% | -65.74% | vs ADGM |
| 5EVGN | $3.48M | $0.40 | -4.99% | -64.71% | -56.46% | -39.70% | vs ADGM |
| 6EOCN | $3.59M | $3.45 | -4.43% | N/A | N/A | N/A | vs ADGM |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$3.33
+2262.4% upside
Low
$3.00
Current
$0.14
High
$4.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.25 | $-0.25 | $-0.25 | 2 |
| Quarter ending Dec 2026 | $-0.26 | $-0.26 | $-0.26 | 2 |
| Quarter ending Mar 2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Quarter ending Jun 2027 | $-0.27 | $-0.27 | $-0.27 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.51 | $-1.09 | $-0.76 | 2 |
| FY 2027 | $-1.61 | $-1.16 | $-0.80 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $200000.00 | $200000.00 | $200000.00 | 1 |
| Quarter ending Jun 2027 | $300000.00 | $300000.00 | $300000.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $1.17M | $1.53M | $1.99M | 2 |
